Cancer Gene Therapy

In Vivo Experiments Compare Two Genetically Engineered Therapies

Published in Gene Therapy Weekly, November 13th, 1995

Retroviral vectors allowed to infect and duplicate in tumor cells provide more therapeutic potential than replication defective retroviral vector producer cells when treating brain tumors.

One strategy for achieving efficient delivery of therapeutic prodrug-activating genes is the stereotactic implantation of fibroblasts that express a foreign gene as well as producing a retroviral vector that bears that gene. Another method involves the grafting of genetically engineered fibroblasts that produce the foreign gene product, but do not replicate in the host.

In order to determine the extent of the differences between the two protocols, T. Tamiya et al....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1995-11-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry